Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau.
J Infect Dis
; 215(8): 1188-1196, 2017 04 15.
Article
em En
| MEDLINE
| ID: mdl-28077730
ABSTRACT
Background:
Children in Guinea-Bissau receive measles vaccine (MV) at 9 months of age, but studies have shown that an additional dose before 9 months of age might have beneficial nonspecific effects. Within a randomized trial designed to examine nonspecific effects of early MV receipt on mortality, we conducted a substudy to investigate the effect of early MV receipt on morbidity.Methods:
Children were randomly assigned at a ratio of 21 to receive 2 doses of MV at 18 weeks and age 9 months (intervention group) or 1 dose of MV at age 9 months, in accordance with current practice (control group). Children were visited weekly from enrollment to age 9 months; the mother reported morbidity, and the field assistants examined the children. Using Cox and binomial regression models, we compared the 2 randomization groups.Results:
Among the 1592 children, early measles vaccination was not associated with a higher risk of the well-known adverse events of fever, rash, and convulsions within the first 14 days. From 15 days after randomization to age 9 months, early measles vaccination was associated with reductions in maternally reported diarrhea (hazard ratio [HR], 0.89; 95% confidence interval [CI], .82-.97), vomiting (HR, 0.86; 95% CI, .75-.98), and fever (HR, 0.93; 95% CI, .87-1.00).Conclusion:
Early MV receipt was associated with reduced general morbidity in the following months, supporting that early MV receipt may improve the general health of children.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Vômito
/
Vacina contra Sarampo
/
Diarreia
/
Imunidade Heteróloga
/
Sarampo
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Infant
/
Male
País/Região como assunto:
Africa
Idioma:
En
Revista:
J Infect Dis
Ano de publicação:
2017
Tipo de documento:
Article
País de afiliação:
Dinamarca